On July 24, Edwards Lifesciences rose 6.05% in regular trading, trading at $87.98/share, with turnover of $38.45 million. The rally was driven by the company's Q2 results that comprehensively exceeded market expectations, coupled with an analyst upgrade.

Edwards reported Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, representing a 16.42% year-over-year increase. Revenue came in at $1.741 billion versus $1.700 billion expected, up from $1.53 billion a year earlier. Core TAVR product sales reached $1.26 billion, growing 11.3% year-over-year and surpassing the $1.23 billion estimate. The company raised its full-year TAVR sales growth guidance lower bound from 7% to 8%, while maintaining adjusted EPS guidance of $2.95 to $3.05.

Following the results, Leerink Partners upgraded Edwards to Outperform from Market Perform and raised its price target to $101 from $87, reflecting increased confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)